Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Notification

Edoxaban and vedolizumab recommended by NICE

The National Institute for Health and Care Excellence has recommended edoxaban (Lixiana; Daiichi Sankyo) as an option for treating and preventing recurrent deep vein thrombosis or pulmonary embolism. Edoxaban is an oral anticoagulant that directly inhibits factor X (factor Xa), which is a key component in the formation of blood clots. In addition, vedolizumab (Entyvio; Takeda) has been recommended as a possible option for adults with moderate to severe Crohn’s disease if tumour necrosis factor (TNF)‑alpha inhibitor isn’t suitable or hasn’t worked well enough. Both medicines will be available on the NHS by November 2015. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069226

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.